Cambridge Healthtech Institute’s 2nd Annual
Engineering Targeted Therapeutics
January 21-22, 2015
The therapeutic potential of antibodies is enhanced by conjugating them to small molecule drugs. This combination merges the benefits of highly potent drugs with selective binders of specific tumor antigens. Antibody-drug conjugates offer the promise of delivering more powerful tumor-killing activity while resulting in diminished side effects for cancer patients. This important Antibody-Drug Conjugates conference brings together leaders in the world of ADCs who share their R&D case studies, along with their preclinical and clinical data, to illustrate how this form of empowered antibody is transforming next-generation antibody therapeutics.
Examination of ADC Safety: Dose-Limiting Toxicities with ADCs
Flavia Brunstein, M.D., Ph.D., Safety Science Leader, Lead, Safety Risk Management, Genentech, Inc.
In vitro-in vivo Molecular Integrity of Antibody-Drug Conjugates: Applying Learning to Clinical Measurements for ADCs
Dan Rock, Ph.D., Scientific Director, Pharmacokinetics and Drug Metabolism, Amgen, Inc.
Mechanistic Models for Designing Efficacious ADCs
Arijit Chakravarty, Ph.D., Senior Scientist II, Modeling and Simulation, DMPK, Takeda Pharmaceuticals
Ags67e, an Anti-Cd37 Monomethyl Auristatin E Antibody (MMAE) Drug Conjugate as a Potential Therapeutic
Daniel S. Pereira, Ph.D., Senior Director, Discovery Research, Agensys, Inc., an Affiliate of Astellas Pharma, Inc.
Novel Bifunctional Linkers for the Synthesis of Homogeneous ADCs
David Jackson, Ph.D., Principal Scientist, Igenica, Inc.
An EGFR Targeting Antibody-Drug Conjugate Engineered for Increased Tumor Specificity
Christopher D. Thanos, Ph.D., Director, New Molecular Entities, Halozyme Therapeutics, Inc.
Brain-Penetrant Peptide-ADC Conjugates Reduce Tumor Size and Increase Survival in Mice with HER2-Positive Brain Tumors
Jean Lachowicz, Ph.D., CSO, Angiochem, Inc.
Building Effective ADCs: Selecting the Right Target, Antibody and Payload
Adeela Kamal, Ph.D., Associate Director, Oncology Research, MedImmune, LLC
Innovative Payload Platform Powers ADC Development
John Lambert, Ph.D., Executive Vice President and CSO, ImmunoGen, Inc.
Delivery of Potent Cytotoxins as ADC Payloads
Vishal Verma, Ph.D., Scientist, Genentech, Inc.
Best-in-Class ADCs; Homogeneity is Necessary but Not Sufficient - Selection of Optimal Conjugation Site is Paramount
Trevor Hallam, Ph.D., CSO, Sutro Biopharma, Inc.